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ABSTRACT
Objective To summarise evidence of the effects of blood 
pressure (BP)- lowering interventions after acute spontaneous 
intracerebral haemorrhage (ICH).
Methods A prespecified systematic review of the 
Cochrane Central Register of Controlled Trials, EMBASE and 
MEDLINE databases from inception to 23 June 2020 to 
identify randomised controlled trials that compared active 
BP- lowering agents versus placebo or intensive versus 
guideline BP- lowering targets for adults <7 days after 
ICH onset. The primary outcome was function (distribution 
of scores on the modified Rankin scale) 90 days after 
randomisation. Radiological outcomes were absolute (>6 mL) 
and proportional (>33%) haematoma growth at 24 hours. 
Meta- analysis used a one- stage approach, adjusted using 
generalised linear mixed models with prespecified covariables 
and trial as a random effect.
Results Of 7094 studies identified, 50 trials involving 11 
494 patients were eligible and 16 (32.0%) shared patient- 
level data from 6221 (54.1%) patients (mean age 64.2 
[SD 12.9], 2266 [36.4%] females) with a median time 
from symptom onset to randomisation of 3.8 hours (IQR 
2.6–5.3). Active/intensive BP- lowering interventions had 
no effect on the primary outcome compared with placebo/
guideline treatment (adjusted OR for unfavourable shift in 
modified Rankin scale scores: 0.97, 95% CI 0.88 to 1.06; 
p=0.50), but there was significant heterogeneity by strategy 
(pinteraction=0.031) and agent (pinteraction <0.0001). Active/
intensive BP- lowering interventions clearly reduced absolute 
(>6 ml, adjusted OR 0.75, 95%CI 0.60 to 0.92; p=0.0077) 
and relative (≥33%, adjusted OR 0.82, 95%CI 0.68 to 0.99; 
p=0.034) haematoma growth.
Interpretation Overall, a broad range of interventions to 
lower BP within 7 days of ICH onset had no overall benefit on 
functional recovery, despite reducing bleeding. The treatment 
effect appeared to vary according to strategy and agent.
PROSPERO registration number CRD42019141136.
INTRODUCTION
Elevated blood pressure (BP) after acute sponta-
neous intracerebral haemorrhage (ICH) is asso-
ciated with adverse clinical outcomes.1–3 Pooled 
individual participant data (IPD) analyses of two 
medium- to- large randomised controlled trials 
(RCTs) of intensive BP lowering initiated early in 
ICH of mild- to- moderate severity (n=3829) suggest 
that achieving and sustaining systolic BP levels as 
low as 120–130 mm Hg in the first 24 hours is safe, 
reduces haematoma expansion and improves func-
tional outcome.4
Current guidelines advocate early intensive BP 
lowering to a systolic target <140 mm Hg after 
acute ICH, based primarily on results of the first 
large RCT to test this strategy, the main phase 
Intensive Blood Pressure Reduction in Acute Cere-
bral Haemorrhage Trial (INTERACT2).5 However, 
a subsequent large trial, the second Antihyperten-
sive Treatment of Acute Cerebral Haemorrhage 
(ATACH- II),6 reported neutral findings, while 
smaller trials of different approaches to BP lowering 
in mixed stroke populations in prehospital7–9 
and in- hospital settings10–12 have reported mixed 
results. Thus, there is ongoing uncertainty over the 
effects of different BP- lowering interventions on 
clinical outcomes, and in relation to the most plau-
sible mechanism of effect, haematoma growth.13–15 
Additionally, the interaction of treatment strategy, 
timing and agent on these effects are unknown.16
IPD meta- analysis is considered the gold stan-
dard for synthesising evidence from RCTs.17 The 
aim of the international Blood pressure in Acute 
Stroke Collaboration (BASC) is to perform detailed 
analyses of pooled IPD from RCTs of BP manage-
ment after acute stroke.18 19 Herein, we present 
results pertaining to the effects of BP- lowering 
interventions on outcomes after acute ICH, with a 
focus on determining whether there is any modi-
fication of the effect by patient characteristics, or 
by the strategy, timing or agent of the BP- lowering 
intervention.
METHODS
Search strategy and selection criteria
We performed a systematic review according to a 
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the effects of different BP- lowering strategies during the acute 
phase (within 7 days) of stroke.20 We identified eligible studies 
in the Cochrane Central Register of Controlled Trials, EMBASE 
and MEDLINE databases from inception to 23 June 2020, and 
in the reference lists of published systematic and ad hoc reviews 
using a comprehensive search strategy, limited to humans, 
combining terms for ICH, BP- lowering interventions and RCTs, 
with no language restrictions.20
We included trials that involved adults (>18 years) with acute 
primary spontaneous ICH (<7 days from onset); randomised 
participants to fixed active agent or intensive, titrated target- 
based BP- lowering interventions with oral, sublingual, trans-
dermal or intravenous agents, in single or combination therapy 
versus placebo or contemporaneous guideline BP management; 
and recorded clinical and/or radiological outcomes.
Two authors screened titles and abstracts, and assessed full- 
text articles for eligibility against the inclusion criteria. We 
sent our protocol and a letter of invitation to investigators of 
eligible studies, inviting them to join the BASC and share IPD. 
We followed with an invitation to join (online or in- person) 
BASC collaborator meetings. To ensure transparency, collabora-
tors sharing data with BASC were asked to sign a data transfer 
agreement for the predefined and appropriate use of their data 
according to our protocol.
Data management
We checked IPD with published results to ensure data were 
complete and transferred without error; queries were resolved 
with individual trial investigators. We harmonised trial datasets 
according to agreed nomenclature. Two minimum datasets for 
primary analyses were developed in Sydney and Nottingham; 
covariable adjustment included trial (treatment allocation, time 
from symptom onset to randomisation), demographic (age and 
sex) and baseline clinical (stroke severity assessed by National 
Institutes of Health Stroke Scale [NIHSS] score21) characteris-
tics. Radiological characteristics were desirable for analyses of 
haematoma growth (time from symptom onset to diagnostic 
brain scan, haematoma volume on baseline and repeat imaging 
24 hours after onset assessed by ABC/222 or semiautomated 
volumetric methods.23
Outcomes
The primary outcome was functional status defined by the ordinal 
distribution of modified Rankin scale (mRS) scores (which range 
from 0 [no symptoms] to 6 [death]) at the end of trial follow- up 
(usually 90 days). Secondary outcomes were: (1) death or depen-
dency (3–6 on the mRS); (2) death or severe dependency (4–6 on 
the mRS) and (3) all- cause death. Radiological outcomes were: 
Figure 1 Study selection. mRS, modified Rankin scale; NIHSS, National 
Institutes of Health Stroke Scale.
Figure 2 Weighted bias plot: (A) all studies and (B) studies that shared patient- level data. Complete bias assessment for individual studies and the design 
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(1) absolute (≥6 mL) and (2) proportional (≥33%) haematoma 
growth at 24 hours.24 Safety outcomes were: (1) early neurolog-
ical deterioration (as defined by each individual trial); (2) symp-
tomatic hypotension (as defined by each individual trial) and (3) 
other any serious adverse event (SAE), as defined by individual 
trial, to include those fatal, non- fatal and treatment related.
Data analysis
We performed primary analysis using the intention- to- treat 
dataset from each trial, with a one- stage approach to IPD meta- 
analysis.25 The one- stage approach provides additional statistical 
power and flexibility by combining all IPD into a single meta- 
analysis, and permits subgroup analyses according to individual 
characteristics of interest (further information in online supple-
mental table 1). We excluded patients without the minimum 
dataset for covariable adjustment. Descriptive statistics are 
described as mean (SD) or median (IQR) for continuous data, or 
frequency (percentage) for categorical data, and Kruskal- Wallis 
or χ2 tests are used to make comparisons.
We used generalised linear mixed models with prespecified 
covariables (age, sex, NIHSS score, time from symptom onset 
to randomisation), and the source trial as a random effect to 
account for clustering. We chose to adjust for the NIHSS score 
as it was previously shown to be a better discriminator of poor 
outcome after acute ICH.26 Analyses of ordinal and binary 
outcome variables are presented as OR with 95% CIs. We 
checked the proportional odds assumption using the likelihood 
ratio test before undertaking ordinal analyses of outcomes on the 
mRS. Analyses of continuous outcome variables are presented as 
mean differences with 95% CIs.
In order to test the modifying effects of patient characteristics, 
and the strategy, timing and agent used in the BP- lowering inter-
ventions on outcomes, we performed the following subgroup 
analysis with an interaction term in models to test heterogeneity: 
age (≤65 vs >65 y), sex, stroke severity (NIHSS score ≤10 vs 
>10), baseline haematoma volume (≤10 vs >10 mL), BP- low-
ering strategy (fixed active agent vs titrated to intensive target), 
time from symptom onset to randomisation (<2 vs 2–6 vs 6–24 
vs ≥24 hour), trial setting (prehospital vs in- hospital), and 
most frequently used BP- lowering agent in the treatment group 
(renin- angiotensin system blocker vs α-adrenoreceptor blocker 
and β-adrenoreceptor blocker vs calcium channel blocker vs 
nitrate vs magnesium). We grouped α-adrenoreceptor blockers 
and β-adrenoreceptor blockers together as included agents 
(intravenous urapidil and labetalol) had varying degrees of α-ad-
renoreceptor and β-adrenoreceptor blocking activity, although 
their effect on BP is primarily achieved through α-adrenore-
ceptor blockade.27 28 For subgroup analyses with three or more 
prespecified subgroups, we explored any patterns that emerged 
in dichotomised subgroups to increase statistical power.
We assessed all eligible studies for bias using the Cochrane 
Collaboration tool (https:// methods. cochrane. org/ bias/) and 
used the robvis risk of bias tool to generate visual summaries.29 
We assessed publication bias by: (1) a visual inspection for funnel 
plot asymmetry and (2) with Egger’s regression test.
We did unadjusted one- stage and adjusted two- stage sensi-
tivity analyses to test the robustness of our findings. Due to 
differences in study designs and outcome reporting for studies 
that did not share IPD (of 34 studies that did not share IPD, 2 
studies reported mRS outcome data; 28 studies did not and in 
2 studies it was unclear, online supplemental table 3), we were 
unable to do the following prespecified analysis for all studies: 
two- stage analysis of the primary outcome using study- level data 
and assessment of publication bias.
To assess confounding from anticoagulant use (64 of 11716 
[3.7%] vs 43 of 1731 [2.5%] with available data in active/inten-
sive versus placebo/guideline groups, respectively),25 we did 
a post hoc sensitivity analysis of the effect of BP lowering on 
absolute and relative haematoma growth at 24 hours with addi-
tional adjustment for anticoagulant use. We observed a pattern 
emerging for a potential interaction effect from the timing of the 
BP- lowering intervention across four prespecified subgroups, so 
we did a post hoc assessment using a dichotomous grouping (<6 
vs ≥6 hours) to maximise statistical power. We also assessed the 
three- way interaction between treatment allocation and timing 
of the BP- lowering intervention by (1) strategy and (2) agent. In 
view of our finding that treatment with intravenous magnesium 
had no effect on BP control during 1–24 hours compared with 
placebo, we did post hoc analysis excluding the trial of intrave-
nous magnesium versus placebo.
Table 1 Characteristics of included patients by randomly allocated 
treatment group
Characteristics







Age, years 64.0 (13.0) 64.3 (12.9) 0.028
Sex (female) 1146/3121 (36.7) 1120/3100 (36.1) 0.012
Geographical region†
  Americas 520/3121 (16.7) 511/3100 (16.5) 0.026
  Asia 1734/3121 (55.6) 1760/3100 (56.8)
  Europe/Australia 867/3121 (27.8) 829/3100 (26.7)
  SBP at randomisation, 
mm Hg
177.3 (20.1) 177.4 (20.5) 0.007
  DBP at randomisation, 
mm Hg
99.9 (15.5) 100.1 (15.8) 0.014
  NIHSS score 11.0 (7.0 to 16.2) 11.1 (7.0 to 16.0) 0.028
  GCS score 14.0 (12.0 to 15.0) 14.0 (13.0 to 15.0) 0.005
  History of hypertension 2219/3023 (73.4) 2179/2998 (72.7) 0.016
  History of diabetes 
mellitus
405/2987 (13.6) 364/2975 (12.2) 0.039
  History of stroke 513/3014 (17.0) 503/2994 (16.8) 0.006
  History of ischaemic 
heart disease
273/2815 (9.7) 275/2827 (9.7) 0.001
  Current use of 
antihypertensive drugs
1194/2653 (45.0) 1183/2652 (44.6) 0.008
  Current antiplatelet 
therapy
163/1734 (9.4) 178/1741 (10.2) 0.028
  Current anticoagulation 64/1716 (3.7) 43/1731 (2.5) 0.072
  Haematoma volume, mL 10.6 (5.1 to 20.5) 10.7 (5.4 to 20.7) 0.037
Haematoma location
  Lobar 249/1942 (12.8) 257/1921 (13.4) 0.017
  Basal ganglia/deep 1589/1942 (81.8) 1547/1921 (80.5) 0.033
  Infratentorial/posterior 
fossa
104/1942 (5.4) 117/1921 (6.1) 0.032
  Intraventricular 
haemorrhage
815/2729 (29.9) 808/2691 (30.0) 0.004
  Time from symptom 
onset to randomisation, 
hour
3.8 (2.5 to 5.4) 3.8 (2.6 to 5.2) 0.018
Process of care variables
  DNAR 133/2177 (6.1) 109/2200 (5.0) 0.051
  Intubation 204/2324 (8.8) 181/2338 (7.7) 0.038
  Neurosurgery 133/2322 (5.7) 142/2338 (6.1) 0.015
Data are numbers (%), mean (SD) or median (IQR).
*A standardised difference of 10% (or 0.1) is equivalent to a p=0.05.
†Geographical region denotes the country in which patients were treated.
DBP, diastolic blood pressure; DNAR, do not attempt resuscitation order; GCS, Glasgow 
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RESULTS
We screened 7094 studies identified through our search strategy, 
assessed 84 full texts for eligibility, invited authors of 50 eligible 
studies to share data and obtained IPD from 16 (32.0%) studies 
(figure 1). This amounted to 6221 of 11 494 (54.1%) partici-
pants recruited to eligible studies; the characteristics of studies 
that did and did not share IPD are summarised in online supple-
mental tables 2 and 3. There were no issues with the integrity 
of IPD, and the studies that shared IPD were at low risk of bias 
(figure 2, online supplemental table 4). We found no evidence of 
publication bias among included studies on a visual inspection of 
the funnel plot and using Egger’s regression test (p=0.11).
Table 1 summarises the baseline characteristics of included 
participants with acute ICH, of whom 3494 (56.2%) were 
recruited in Asia, 1696 (27.2%) in Europe/Australia and 1031 
(16.6%) in the Americas. Baseline demographic and clinical 
characteristics were well balanced between 3121 participants 
randomly assigned to active/intensive BP management, and 3100 
to placebo/guideline BP management. Overall, their mean age 
was 64.2 (SD 12.9) years and 2266 (36.4%) were female, with 
a median level of baseline neurological impairment, defined by 
NIHSS score of 11 (range 0–42, IQR 7–16). Overall mean systolic 
and diastolic BP at randomisation were 177.3 mm Hg (SD 20.3) 
and 100.0 mm Hg (SD 15.7), respectively, and the median time 
from onset to randomisation to various BP- lowering strategies 
was 3.8 hours (IQR 2.6–5.3). The median haematoma volume 
on the diagnostic CT brain scan was 10.7 mL (IQR 5.2–20.7).
There were 5895 (94.8%) patients with complete IPD for 
adjusted analysis of the primary outcome. There were 326 (5.2%) 
patients without the minimum required data excluded from anal-
yses: 120 (2.0%), 203 (3.3%) and 38 (0.6%) were missing data 
on mRS scores, NIHSS scores, and time from symptom onset to 
randomisation, respectively. Due to differences in the aims and 
designs of trials sharing IPD, there were 2510 (43.1%) patients 
with IPD and a CT scan reassessment at 24 hours for analysis of 
the key radiological outcome of haematoma growth.
Compared with patients who received placebo/guideline BP 
management, BP was significantly lower in patients who received 
active/intensive management: mean differences in mean systolic 
BP were −7.5 mm Hg (95% CI −8.6 to −6.3; p<0.0001), 
–12.1 mm Hg (95% CI −13.0 to −11.2; p<0.0001) and −7.3 
mm Hg (95% CI −8.2 to −6.5; p<0.0001) within 1 hour, 1–24 
hours and during 2–7 days, respectively; mean differences in 
diastolic BP in the same time epochs were −3.8 mm Hg (95% CI 
−4.8 to −2.8; p<0.001), –5.3 mm Hg (95% CI −6.0 to −4.5; 
p<0.001) and −3.9 mm Hg (95% CI −4.6 to −3.3; p<0.001). 
Table 2 Effect of active/intensive versus placebo/guideline blood pressure lowering interventions on outcomes after acute intracerebral 
haemorrhage (ICH)
Outcome
Randomly allocated treatment group
Adjusted OR* (95% CI) P valueActive/intensive Placebo/guideline
Primary: unfavourable shift in modified Rankin Scale (mRS) scores /3062 /3039 0.97 (0.88 to 1.06) 0.50
0 206 (6.7) 219 (7.2)
1 566 (18.5) 525 (17.3)
2 555 (18.1) 553 (18.2)
3 521 (17.0) 514 (16.9)
4 582 (19.0) 578 (19.0)
5 221 (7.2) 245 (8.1)
6 411 (13.4) 405 (13.3)
Secondary /3062 /3039
Dependency or death (mRS 3–6) 1735 (56.7) 1742 (57.3) 0.95 (0.84 to 1.08) 0.42
Severe dependency or death (mRS 4–6) 1214 (39.7) 1228 (40.4) 0.95 (0.84 to 1.08) 0.41
Death 411/3111 (13.2) 405/3087 (13.1) 1.01 (0.85 to 1.20) 0.91
Safety outcomes
Any SAE 781/3000 (26.0) 727/2982 (24.4) 1.13 (0.99 to 1.29) 0.07
Neurological deterioration† 304/2911 (10.4) 300/2913 (10.3) 1.02 (0.86 to 1.22) 0.81
Severe hypotension† 25/2831 (0.9) 15/2840 (0.5) 1.73 (0.89 to 3.37) 0.11
Cardiac SAE 69/2978 (2.3) 70/2980 (2.3) 1.01 (0.72 to 1.42) 0.96
Renal SAE 34/2978 (1.1) 28/2980 (0.9) 1.26 (0.75 to 2.09) 0.38
Haematoma growth at 24 hours‡
Mean growth (95% CI), mL 3.2 (2.5 to 3.9) 4.3 (3.4 to 5.2) Absolute difference: −1.10 (−2.22 to 0.01) 0.05
Absolute growth ≥6 mL 212/1280 (16.6) 252/1230 (20.5) 0.75 (0.60 to 0.92)§ 0.007
Relative growth ≥33% 296/1280 (23.1) 326/1230 (26.5) 0.82 (0.68 to 0.99)§ 0.03
*Model adjusted for age, sex, National Institutes for Health Stroke Scale score, time from onset to randomisation and trial (random effect); all patients followed up for 90 days 
except those in the Scandinavian Candesartan Acute Stroke Trial who were followed for 6 months.
†Treatment related, as defined by each trial.
‡Trials contributing data for analyses of haematoma growth at 24 hours: INTERACT1&2, ICH- ADAPT, ATACH- II, FAST- MAG.
§Model adjusted for age, sex, baseline haematoma volume and time from symptom onset to randomisation.
CI, confidence interval; mRS, modified Rankin Scale; OR, odds ratio; SAE, serious adverse event.
Figure 3 Distribution of scores on the modified Rankin Scale (mRS) in 
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Postrandomisation BP control during 1–24 hours varied across 
individual studies in a two- stage approach: compared with their 
respective controls, larger mean reductions in systolic BP were 
achieved in patients randomised to intensive, titrated target- 
based BP- lowering strategies compared with patients randomised 
to fixed active agent- based BP- lowering strategies.
Table 2 shows the randomised treatment effect of BP- lowering 
interventions on the primary, secondary, safety and radiolog-
ical outcomes, using a one- stage approach. The proportional 
odds assumption was fulfilled using the likelihood ratio test for 
ordinal analyses of the primary outcome of functional status 
assessed across the 7- levels of the mRS. Overall, there was no 
effect of active/intensive BP management on the distribution of 
mRS scores at the end of trial follow- up (mRS data for 5830 
patients from 12 studies at 90 days, 271 patients from 1 study 
at 180 days): adjusted OR for unfavourable shift in mRS scores 
0.97 (95% CI 0.88 to 1.06; p=0.50), table 2 and figure 3. This 
finding was consistent across various standard cut points on the 
mRS that reflect greater disability (table 2), in prespecified sensi-
tivity analyses using adjusted two- stage and unadjusted one- stage 
models, and after adjustment for Glasgow Coma Scale score 
rather than NIHSS score (online supplemental table 5). There 
was no effect of treatment allocation on death: adjusted OR 1.01 
(95% CI 0.85 to 1.20; p=0.91).
We assessed heterogeneity in the treatment effect on the 
primary outcome across prespecified subgroups (figure 4). A 
significant interaction existed for BP- lowering strategy (pinterac-
tion=0.031): there was a non- significant increase in the odds for 
unfavourable shift in mRS scores in patients treated with fixed 
active BP- lowering agents (adjusted OR 1.17, 95% CI 0.97 to 
1.41), compared with a non- significant decrease in the odds for 
unfavourable shift in mRS scores for patients treated with BP 
lowering titrated to an intensive target (0.91, 95% CI 0.82 to 
1.02). Additionally, heterogeneity was noted between different 
BP- lowering agents (pinteraction <0.0001): patients treated with 
renin–angiotensin system blockers had significantly increased 
odds for unfavourable shift in mRS scores (adjusted OR 1.57, 
95% CI 1.00 to 2.45), while patients treated with α-adreno-
receptor and β-adrenoreceptor blockers and calcium channel 
blockers had non- significant reductions in the odds for unfa-
vourable shift in mRS scores (adjusted OR 0.90, 95% CI 0.80 
to 1.02, and adjusted OR 0.94, 95% CI 0.77 to 1.15, respec-
tively). There was no significant interaction according to timing 
of BP- lowering intervention. The results did not change in a post 
hoc sensitivity analysis where patients from a trial of intravenous 
magnesium versus placebo were excluded.
In post hoc analysis, there was no evidence of heterogeneity 
in the effect of BP- lowering interventions initiated earlier (<6 
hours) compared with later (≥6 hours) after the onset of symp-
toms (OR for unfavourable shift in mRS scores: 0.93, 95% CI 
0.84 to 1.03, vs OR 1.20, 95% CI 0.96 to 1.49; pinteraction=0.081). 
Three- way interactions between treatment allocation, the timing 
of the BP- lowering intervention and (1) the strategy (fixed active 
agent vs intensive target) and (2) the agent were not statistically 
significant (pinteraction=0.652 and pinteraction=0.571, respectively).
Table 2 also shows there was no difference in the number of 
patients with any SAE between active/intensive and placebo/
guideline groups, nor in neurological deterioration, severe hypo-
tension or cardiac or renal SAE.
There were 2510 patients from 5 trials with complete IPD 
for adjusted analysis of the secondary outcome of haematoma 
growth at 24 hours (table 2). The absolute difference in haema-
toma growth at 24 hours between active/intensive BP manage-
ment and placebo/guideline BP management was −1.10 mL 
(−2.22 to 0.01) mL, p=0.05. Compared with placebo/guide-
line BP management, active/intensive BP- lowering interventions 
reduced the odds of haematoma growth, when assessed either 
by an absolute (>6 mL, adjusted OR 0.75, 95% CI 0.60 to 
0.92; p=0.0077) or relative (≥33%, adjusted OR 0.82, 95% 
CI 0.68 to 0.99; p=0.034) increase between baseline and 24 
hours. There was no heterogeneity in the treatment effect across 
prespecified subgroups (figure 5).
DISCUSSION
In this meta- analysis of patient- level data from RCTs of various 
BP- lowering interventions in adults with predominantly mild- to- 
moderate severity acute ICH, we have shown that a moderate 
degree of BP lowering does not improve functional outcome 
by 3–6 months. However, BP lowering can reduce the risk of 
haematoma growth—a factor strongly associated with poor 
outcome30 31—in a similar manner according to patient age, sex 
and baseline haematoma volume. We have also provided new 
information about the potential for heterogeneity in the effects 
of BP lowering according to the treatment strategy and agent.
There has been uncertainty about the most effective strategy 
for lowering BP after acute ICH.13 16 Our study included patients 
treated with a broad range of interventions by which to make 
comparisons: in prespecified subgroup analysis, we found 
significant heterogeneity in the treatment effect according to 
the strategy used to deliver BP lowering. Patients who received 
BP- lowering interventions titrated to an intensive target had 
larger reductions in their systolic BP and seemed to have better 
functional outcome compared with patients treated with a fixed 
active agent. These findings are supported by previous observa-
tional analysis of pooled data from two RCTs (n=3829) which 
Figure 4 Effects of blood pressure (BP) lowering interventions in 
active/intensive versus placebo/guideline groups after acute intracerebral 
haemorrhage on the primary outcome in subgroups. Model adjusted for 
age, sex, National Institutes for Health Stroke Scale (NIHSS) score and 
time from symptom onset to randomisation. §SCAST; †INTERACT1&2, 
ICH- ADAPT; ¥ ATACH- II, CHASE, Koch 2018, VENUS; # GTN1&2, ENOS, 
RIGHT1&2; ʃ FAST- MAG. copyright.
 on N
ovem
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suggested that careful, targeted and sustained reductions in 
systolic BP (to as low as 120–130 mm Hg in the first 24 hours) 
are safe, and associated with better functional outcome.4
Uncertainty also persists about the most effective agent for 
lowering BP after acute ICH.15 16 Our study included patients 
who were treated with various BP- lowering agents that were 
delivered via intravenous, oral, sublingual and transdermal 
routes. Our prespecified subgroup analysis showed that the 
effects of interventions varied according to the categorisation of 
each trial by the most frequently used agent in the treatment 
arm, with patients treated in trials of predominantly intravenous 
α-adrenoreceptor and β-adrenoreceptor blockers appearing to 
have better functional outcome compared with patients treated 
with other agents. This might be explained by the potential for 
intravenous α-adrenoreceptor and β-adrenoreceptor blockers to 
target peripheral arteriolar resistance and attenuate the sympa-
thetic response that has been shown to determine high admission 
BP after acute ICH.32 Their use may also avoid the potential 
deleterious effects of vasodilation associated with ultraearly 
use of topical nitrates.33 However, more data are needed: the 
recently initiated, INTEnsive ambulance- delivered blood pres-
sure Reduction in hyper- Acute stroke (INTERACT4) trial, aims 
to determine if prehospital administered BP lowering with 
the intravenous α-adrenoreceptor blocker urapidil, improves 
outcome in patients with a diagnosis of ICH ( ClinicalTrials. gov: 
NCT03790800).
The large pooled dataset also allowed us to test the ‘time is 
brain’ hypothesis in relation to BP lowering after ICH. Another 
IPD meta- analysis has shown that time to diagnostic imaging, 
baseline haematoma volume and anticoagulant use at symptom 
onset were the key predictors of subsequent haematoma growth: 
the earlier the scan and larger the haematoma, the greater the 
risk of growth, peaking at 0.5–3 hours after symptom onset 
and a volume of 75 mL, respectively.24 More recently, post hoc 
analyses of the ATACH- II trial have suggested a benefit of BP 
lowering in patients who received the treatment within 2 hours 
of symptom onset.34 In our study, where median time to rando-
misation and baseline haematoma volume were 3.8 hours and 
10.7 mL, respectively, greater reductions in haematoma growth 
seemed to occur in patients in whom treatment was initiated 
between 2 and 4 hours compared with other time periods from 
symptom onset, but without there being statistical heterogeneity 
across the subgroups. The absence of effect in patients treated 
earlier may be due to a substantial proportion of patients in 
the <2 hours subgroup being from prehospital studies of intrave-
nous magnesium (which had no demonstrable effect on BP) and 
topical nitrates (which may be harmful very early after ICH due 
to their vasodilatory properties33). Further research is awaited 
to validate previous findings about ultraearly nitrate use (Multi-
centre Randomised trial of Acute Stroke treatment in the Ambu-
lance with a nitroglycerin Patch, MR ASAP, ISRCTN99503308) 
and between 3 and 5 hours after the onset of symptoms (Effi-
cacy of Nitric Oxide in Stroke- 2, EudraCT 2020- 001304- 42), 
and establish the safety of other agents in the prehospital setting 
(INTERACT4, NCT03790800).
Key strengths of this study are the broad inclusion criteria 
and availability of IPD from most high- quality ICH and mixed 
stroke trials in the area. This increased the sample of patients 
with ICH to 6221, compared with 4360 in a previous study- level 
meta- analysis of ICH studies only.14 The unique dataset facili-
tated robust covariable- adjusted analyses which provide reliable 
evidence about the effect of BP- lowering on ICH growth. The 
analyses were also adequately powered to detect heterogeneity in 
treatment effect according to various aspects of the BP- lowering 
interventions, including strategy, timing and most frequently 
used agent. We acknowledge that a lack of IPD from various 
small (n<250) studies raises the possibility of data availability 
bias, but many of these had a high risk of bias and reported 
Figure 5 Effects of blood pressure (BP) lowering interventions in active/intensive versus placebo/guideline groups after acute intracerebral haemorrhage 
(ICH) on absolute haematoma growth ≥6 mL at 24 hours in subgroups. Model adjusted for age, sex, baseline haematoma volume and time from symptom 
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outcomes that were not suitable for meta- analysis and thus, are 
unlikely to have influenced our overall results and conclusions. 
Although we had a reasonably large sample (n=2510) for anal-
yses of the effects of BP lowering on haematoma growth, the 
majority of patients contributing data came from studies that 
tested early intensive, titrated target- based BP lowering. Other 
notable limitations fail to resolve uncertainty over the mecha-
nisms underpinning the main findings: first, our assessment of 
drug- class effects was based on the most frequently used agent in 
the active/intensive treatment group of each trial; the frequent use 
of rescue agents/multiagent regimens for resistant hypertension 
limits the reliability of any conclusions made about a preferred 
agent. Second, despite the benefits of a large sample size and 
greater statistical precision, the current analyses may have failed 
to detect complex multilevel interactions between setting, timing 
and strategy. Third, our analyses do not account for the speed 
and degree of BP lowering, where the potential risks (end- organ 
ischaemia) and benefits (reductions in haematoma growth) of 
treatment may be finely balanced. Finally, we were unable to 
adjust for other potential confounders of outcome after acute 
ICH including race/ethnicity, time to drug administration, with-
drawal of active care35 and poor baseline kidney function36 as 
these variables were not acquired from several studies.
In summary, our findings reinforce complexities to the genera-
tion of evidence over treatments for acute ICH. We have shown 
that while moderate BP reduction, applied within several hours 
of the onset of ICH, is safe and reduces the likelihood of growth 
of small- to- medium sized haematomas, this does not clearly 
translate into improved odds of recovery. Subgroup analyses 
suggest that BP- lowering interventions may be more effective if 
they are titrated to an intensive target rather than applied as 
a fixed dose of an active agent, or involve drugs with prefer-
ential α-adrenoreceptor and β-adrenoreceptor blockade rather 
than involving calcium channel blockers, nitrates or angiotensin 
system blockers.
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